Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Longitudinal Study of the Clinical and Haematological Cause of Women With Antiphospholipid Antibodies.

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2005 by Imperial College London.
Recruitment status was  Recruiting
Information provided by:
Imperial College London Identifier:
First received: September 13, 2005
Last updated: NA
Last verified: September 2005
History: No changes posted
This study is being done to see if there are any long term health related issues in women with APA and recurrent miscarriages.

Antiphospholipid Syndrome

Study Type: Observational
Study Design: Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Retrospective/Prospective
Official Title: Longitudinal Study of the Clinical and Haematological Cause of Women With Antiphospholipid Antibodies in Women Presenting as Recurrent Miscarriages.

Resource links provided by NLM:

Further study details as provided by Imperial College London:

Estimated Enrollment: 250
Study Start Date: September 1998
Estimated Study Completion Date: August 2005
Detailed Description:
The association between APA and thrombosis is well documented. Both LA and ACA are often detected in individuals with SLE but there is no prospective data on the risk of thrombosis in women who present with recurrent miscarriages in association with APA. This study should significantly advance medical knowledge of the natural history of primary antiphospholipid syndrome (PAPS) which is essential to enable optimal management of relatively young women who may be at risk of complications, some of which are potentially life threatening.

Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Antiphospholipid syndrome History of recurrent miscarriages

Exclusion Criteria:

Previous thromboembolic disease

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00180817

Contact: Lesley Regan, FRCOG 02078861050

United Kingdom
St. Mary's Hospital Recruiting
London, United Kingdom, W2 1NY
Contact: Lesley Regan, FRCOG    02078861050   
Principal Investigator: Lesley Regan, FRCOG         
Sponsors and Collaborators
Imperial College London
Principal Investigator: Lesley Regan Imperial College London
Principal Investigator: Raj Rai, MRCOG Imperial College London
Principal Investigator: Winnie Lo St. Mary's NHS Trust, London
Principal Investigator: Preeti Jindal, MRCOG St. Mary's NHS Trust, London
  More Information Identifier: NCT00180817     History of Changes
Other Study ID Numbers: EC3103 
Study First Received: September 13, 2005
Last Updated: September 13, 2005
Health Authority: United Kingdom: Research Ethics Committee

Additional relevant MeSH terms:
Antiphospholipid Syndrome
Autoimmune Diseases
Immune System Diseases
Antibodies, Antiphospholipid
Immunologic Factors
Physiological Effects of Drugs processed this record on October 27, 2016